Targeted α-particle radiotherapy with 211At-labeled monoclonal antibodies
MR Zalutsky, DA Reardon, OR Pozzi… - Nuclear medicine and …, 2007 - Elsevier
An attractive feature of targeted radionuclide therapy is the ability to select radionuclides and
targeting vehicles with characteristics that are best suited for a particular clinical application…
targeting vehicles with characteristics that are best suited for a particular clinical application…
Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to α-particle emitting 211At
AA Rosenkranz, G Vaidyanathan, OR Pozzi… - International Journal of …, 2008 - Elsevier
PURPOSE: To generate and evaluate a modular recombinant transporter (MRT) for
targeting 211 At to cancer cells overexpressing the epidermal growth factor receptor (EGFR). …
targeting 211 At to cancer cells overexpressing the epidermal growth factor receptor (EGFR). …
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 3: α-particle–induced radiolytic effects on the chemical behavior of 211At
OR Pozzi, MR Zalutsky - Journal of Nuclear Medicine, 2007 - Soc Nuclear Med
Two characteristics of α-particles that enhance their potential for targeted radiotherapy are
their high energy and approximately cellular range. Unfortunately, these properties also can …
their high energy and approximately cellular range. Unfortunately, these properties also can …
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 2: radiolytic effects of 211At α-particles influence N-succinimidyl 3-211At-astatobenzoate synthesis
OR Pozzi, MR Zalutsky - Journal of Nuclear Medicine, 2005 - Soc Nuclear Med
A variety of promising targeted radiotherapeutics labeled with α-emitters have been
developed. Clinical investigation of these radiopharmaceuticals requires the production of high …
developed. Clinical investigation of these radiopharmaceuticals requires the production of high …
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At α-particles
OR Pozzi, MR Zalutsky - Journal of Nuclear Medicine, 2005 - Soc Nuclear Med
The high energy and short range of α-particles make them attractive for targeted radiotherapy.
However, these properties can be problematic when the production of high activity levels …
However, these properties can be problematic when the production of high activity levels …
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At α-particles
OR Pozzi, MR Zalutsky - Nuclear medicine and biology, 2017 - Elsevier
Introduction Alpha particles are radiation of high energy and short range, properties that can
lead to radiolysis-mediated complications in labeling chemistry at the high radioactivity …
lead to radiolysis-mediated complications in labeling chemistry at the high radioactivity …
Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor
G Vaidyanathan, OR Pozzi, J Choi… - Cancer Biotherapy & …, 2020 - liebertpub.com
Background: In a previous clinical study, the authors evaluated the potential of antitenascin
C monoclonal antibody (mAb) 81C6 labeled with 211 At via the prosthetic agent N-…
C monoclonal antibody (mAb) 81C6 labeled with 211 At via the prosthetic agent N-…
Influence of prosthetic radioiodination on the chemical and biological behavior of chemotactic peptides labeled at high specific activity
OR Pozzi, EO Sajaroff, MM Edreira - Applied radiation and isotopes, 2006 - Elsevier
The influence of radioiodination made through prosthetic group N-succinimidyl-3-[ 131 I]iodo-benzoate
([ 131 I]SIB) on the behavior of small peptides was investigated using as model …
([ 131 I]SIB) on the behavior of small peptides was investigated using as model …
Iodide benzamides for the in-vivo detection of melanoma and metastases
MM Edreira, OR Pozzi - Melanoma Research, 2006 - journals.lww.com
The aim of this work was to synthesize, label and evaluate in vivo [131 I] N-(2-diethylaminoethyl)-3-iodo-4-methoxybenzamide
([131 I] IMBA) as a radiotracer for B16-F0 melanoma cells, …
([131 I] IMBA) as a radiotracer for B16-F0 melanoma cells, …
131/123 iodine labeled benzamides for the detection of melanomas and metastases. Synthesis, labeling, animal experiences and preliminary clinical studies; …
OR Pozzi, MM Edreira, SG Castiglia, AC Zarlenga… - 1999 - osti.gov
Radioiodine labeled benzamides are being studied as radiopharmaceuticals for the
detection of melanomas and metastases. With this purpose the synthesis and labeling of N-(2-…
detection of melanomas and metastases. With this purpose the synthesis and labeling of N-(2-…